SCHEMBL16184780

SCHEMBL16184780

COc1cc(-c2cc(F)ccc2F)cc2c(N3CCC3)nc(-c3cccnc3)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.45
▸ ALDH1A1 P00352 5/20 0.45
▸ LMNA P02545 3/20 0.45
▸ NPSR1 Q6W5P4 3/20 0.45
▸ GAA P10253 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.42
▸ STAT6 P42226 1/20 0.42
▸ GBA1 P04062 6/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ ALOX15 P16050 2/20 0.41
▸ CLK4 Q9HAZ1 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184770 0.98 MAPT (0.47) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184778 0.97 MAPT (0.48) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184047 0.94 MAPT (0.45) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184781 0.93 CYP1A2 (0.51) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184777 0.92 ALDH1A1 (0.50) MAPTALDH1A1LMNAGAAUSP2
SCHEMBL16184755 0.92 MAPT (0.48) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184761 0.91 MAPT (0.49) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184053 0.91 MAPT (0.48) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184786 0.90 BACE1 (0.43) MAPTALDH1A1LMNANPSR1GAA
SCHEMBL16184784 0.89 GBA1 (0.44) MAPTALDH1A1LMNANPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885ALDH1A1 1687/4885LMNA 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback